Stenting with or without Protection in High-Risk Patients with Moderate to High-Grade Carotid Stenosis Presented at ACC 2003 Late Breaking Clinical Trials.

Slides:

Advertisements

Similar presentations

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.

Advertisements

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Is Carotid Stenting an Option for Treatment of Carotid Stenosis? Joint Hospital Surgical Grand Round WH WONG Queen Mary Hospital.

Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy Presented by Jay Yadav, MD on behalf of the SAPPHIRE Investigators.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.

Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006 Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006.

Carotid Stenting Review Renan Uflacker, MD Interventional Radiology Medical University of South Carolina.

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.

Endovascular Management of Intracranial and Extracranial Atherosclerosis Rishi Gupta, MD Associate Professor of Neurology, Neurosurgery, and Radiology.

Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.

Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.

Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.

Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.

UPDATE IN CAROTID ARTERY STENTING & STROKE MANAGEMENT Dr. Nikolaos Melas, PhD Vascular and Endovascular Surgeon Military Doctor Associate in 1st department.

Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.

EPIC Trial Evaluating the Use of the FiberNet ® Embolic Protection System In Carotid Artery Stenting Subbarao Myla, MD FACC Principal Investigator & Medical.

Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.

Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.

Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Carotid Disease – Stent vs Surgery vs Medical Therapy? Mehdi H. Shishehbor, DO, MPH, PhD Director, Endovascular Services Interventional Cardiology & Vascular.

0 0 Lenox Hill Heart and Vascular Institute of New York SCAI 2005 CAROTID STENTING Clinical Trial Overview SRIRAM S. IYER Lenox Hill Hospital, New York.

The STAR Study. Cardiovascular Disease Antihypertensives The STAR Study Stent Placement in Patients with Atherosclerotic Renal Artery Stenosis and Impaired.

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

Emerging Techniques For Management of Carotid and Brachiocephalic Occlusive Disease for Prevention of Stroke Brian Whang, Romeo Mateo, Anthony Pucillo,

(p for noninferiority = 0.01)

The American College of Cardiology Presented by Dr. Adnan Kastrati

Recent Update on Carotid Endarterectomy versus Carotid Artery Stenting

Carotid Artery Stenosis

CQC Amit Gossain.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

The IDEAL Study Reference

The American Heart Association Presented by Dr. Steven E. Nissen

Carotid Artery Stenting for Stroke Prevention

Stenting of Coronary Arteries in Non Stress/Benestent Disease

SIRIUS Trial: Diameter Restenosis

American College of Cardiology Presented by Dr. Stephan Windecker

Late Breaking Clinical Trials

REALITY: 8 month results

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

Current update of cerebral embolic protection devices

Carotid Artery Stenting for Stroke Prevention

Presented at ACC 2003 Late Breaking Clinical Trials

The American College of Cardiology Presented by Dr. Raimund Erbel

SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.

Carotid endarterectomy was performed with lower stroke and death rates than carotid artery stenting in the United States in 2003 and 2004 James T. McPhee,

Drug-eluting stents for in-stent restenosis

Elevated Admission Plasma Glucose Following ACS

DECLARE-TIMI 58.

ACC 2003 Late Breaking Trials

ARISE Trial Aggressive Reduction of Inflammation Stops Events

American College of Cardiology Presented by Dr. Adnan Kastrati

The American College of Cardiology Presented by Dr. A. Abazid

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Craig R. Narins, MD, Karl A. Illig, MD Journal of Vascular Surgery

Presentation transcript:

Stenting with or without Protection in High-Risk Patients with Moderate to High-Grade Carotid Stenosis Presented at ACC 2003 Late Breaking Clinical Trials ARCHER Trial

www. Clinical trial results.org ARCHER 437 high-risk patients with moderate to high- grade carotid stenosis  >50% stenosis in symptomatic patients  >80% stenosis in asymptomatic patients  >1 co-morbid condition: >2 vessels with > 70% stenosis; MI within 30 days; unstable angina; EF III; COPD; dialysis for chronic renal failure; uncontrolled diabetes; restenotic lesion after CEA 437 high-risk patients with moderate to high- grade carotid stenosis  >50% stenosis in symptomatic patients  >80% stenosis in asymptomatic patients  >1 co-morbid condition: >2 vessels with > 70% stenosis; MI within 30 days; unstable angina; EF III; COPD; dialysis for chronic renal failure; uncontrolled diabetes; restenotic lesion after CEA Treatment Group A ACCULINK™ Carotid Stent System + ACCUNET™ Embolic Protection System (n = 278) Treatment Group A ACCULINK™ Carotid Stent System + ACCUNET™ Embolic Protection System (n = 278) Treatment Group B ACCULINK™ Carotid Stent System without protection (n = 159) Treatment Group B ACCULINK™ Carotid Stent System without protection (n = 159) Endpoints:  Primary – 30 day Death, Stroke or MI Endpoints:  Primary – 30 day Death, Stroke or MI ACC 2003 Late Breaking Trials

www. Clinical trial results.org Death/ MI/ Stroke Death/ MI/ Stroke : 30 Day Event Rates ARCHER : 30 Day Event Rates ACC 2003 Late Breaking Trials Stroke Death MI